Stock Information

• Jim Cramer Shares Key Trend For Johnson & Johnson (JNJ) Shares
  Sat, May 2, 2026 6:08 AM
• Is Johnson & Johnson (JNJ) Still Fairly Priced After Its Strong 1-Year Share Price Run?
  Sat, May 2, 2026 4:28 AM
• Johnson & Johnson : STELARA® Pediatric Crohn’s Disease FDA Approval J&J Statement
  Fri, May 1, 2026 4:21 PM
• S&P 500's Best‑Kept Secret: Why Healthcare Could Be 2026's Breakout Winner
  Fri, May 1, 2026 4:07 PM
• Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio
  Fri, May 1, 2026 3:45 PM
• Eli Lilly Stock’s Path To 30% Upside
  Fri, May 1, 2026 2:50 PM
• Chlorpheniramine Maleate - Global Market Insights, Competitive Landscape & Industry Forecast to 2033 Featuring Viatris, Alkem Labs, Merck & Co., Johnson & Johnson, Capellon Pharma and More
  Fri, May 1, 2026 1:45 PM
• Johnson & Johnson statement on investigational programs in large B-cell lymphoma
  Thu, Apr 30, 2026 7:38 PM
• Jim Cramer Says “Organon’s Done” Upon a Caller’s Inquiry
  Thu, Apr 30, 2026 7:18 PM
• Johnson & Johnson Statement On Investigational Programs In Large B-cell Lymphoma; To Discontinue CD20 And CD19-CD20 CAR-T Programs; To Continue Support For Patients In Discontinued Investigational CD20 Mono CAR-T Cell Therapy And CD19-CD20 bi-CAR-T Programs
  Thu, Apr 30, 2026 5:18 PM

Financial data not available